Document is current
Any future updates will be listed below
-
Authors
Lebbe, Celeste
Ravimohan, Shruthi
Datta, Antara
Chhibber, Aparna
Couselo, Eva Muñoz
Pereira, Caio
Sandhu, Shahneen
Zhou, Ming
Curti, Brendan
Khushalani, Nikhil
Taylor, Matthew
Eertwegh, Alfonsus Van Den
Hoch, Ute
AO, Georgina Long
Arriaga, Yull
Diab, Adi
Gogas, Helen
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03635983 at ClinicalTrials.govDocuments that mention this clinical trial
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT
https://doi.org/10.1136/jitc-2021-004218
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2025-012885
1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial
https://doi.org/10.1136/jitc-2022-sitc2022.1473
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancer
https://doi.org/10.1136/jitc-2019-000464
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
https://doi.org/10.1200/jco.23.00172
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
https://doi.org/10.1136/jitc-2020-sitc2020.0420
